BJDX
Bluejay Diagnostics, Inc.0.9664
-0.0436-4.32%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.75MP/E (TTM)
0.01Basic EPS (TTM)
164.37Dividend Yield
0%Recent Filings
10-Q
8-K
Bluejay expands Symphony manufacturing
Bluejay Diagnostics expanded its partnership with Sanyoseiko on October 3, 2025, amending master agreements to boost commercialization of the Symphony platform for rapid IL-6 testing in sepsis. Sanyoseiko now handles end-to-end manufacturing redevelopment, raw material sourcing, vendor compliance, kit assembly, packaging, shipping, quality control, and regulatory support. This bolsters supply chain resilience. Yet commercialization hinges on FDA clearance.
8-K
Board leadership reshuffle announced
Bluejay Diagnostics reshuffled its board leadership on August 15, 2025, appointing Donald R. Chase as Chairperson, succeeding Douglas C. Wurth, who took over the Nominating and Corporate Governance Committee chair from Fred S. Zeidman; Zeidman now leads the Compensation Committee, while Chase retains Audit Committee duties. These changes, effective immediately, stem from routine governance review. All three directors remain independent under Nasdaq and SEC rules. Shifts signal steady oversight.
8-K
SYMON-II trial enrollment begins
Bluejay Diagnostics kicked off patient enrollment in the SYMON-II pivotal trial on August 7, 2025, building on SYMON-I to validate IL-6 levels' role in predicting 28-day mortality for ICU sepsis patients. The company amended its Toray Industries agreement on July 23, 2025, pushing cartridge manufacturing independence to October 2026, while aligning with SanyoSeiko for analyzer production. SYMON-II testing wraps by end-2026, eyeing FDA 510(k) in 2027. Additional funding is essential through 2027.
10-Q
Q2 FY2025 results
Bluejay Diagnostics narrowed its operating loss to $2.0 million in Q2 FY2025 ended June 30, 2025, up from $1.9 million a year earlier, while year-to-date losses eased to $3.9 million from $4.3 million, thanks to trimmed R&D spending on clinical trials and tech transfers. No revenue yet, but cash burn slowed, with operating cash use at $3.2 million for the half versus $4.2 million last year; free cash flow not disclosed in the 10-Q. Cash stood at $4.4 million against $1.0 million in current liabilities, bolstered by a $3.8 million warrant inducement in April, yet the firm flags substantial going-concern doubts without fresh funding soon. Redevelopment of Symphony cartridges advances via third-party contractors, eyeing a 510(k) submission in 2027 if financed. Cash lasts to Q4 2025. Reverse stock splits since 2023 adjusted EPS comparability. Competition from larger biotech players looms large.
BDX
Becton, Dickinson and Company
196.39-3.70
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BMRA
Biomerica, Inc.
2.37-0.08
BRKR
Bruker Corporation
44.96-0.71
CODX
Co-Diagnostics, Inc.
0.25-0.02
DGX
Quest Diagnostics Incorporated
178.66-5.45
IDXG
Interpace Biosciences, Inc.
1.14-0.02
LUCD
Lucid Diagnostics Inc.
1.12+0.01
QTRX
Quanterix Corporation
7.36-0.05